What to Expect When Requesting Elunate (Fruquintinib) in India

 

Buy Fruquintinib (Elunate/Fruzaqla) tablets/ capsules online in India 

For patients with refractory metastatic colorectal cancer (mCRC), treatment options become increasingly limited once the disease progresses despite standard chemotherapy and targeted therapies. In such situations, Fruquintinib (Elunate) has emerged as an important targeted therapy that offers a new treatment option for eligible patients.

Elunate contains Fruquintinib, a highly selective oral vascular endothelial growth factor receptor or VEGFR inhibitor. It works by selectively blocking VEGFR-1, VEGFR-2, and VEGFR-3, which are responsible for the formation of new blood vessels that tumors need to grow and spread. By inhibiting these receptors, Elunate helps reduce the blood supply to tumors, thereby slowing tumor growth and disease progression. It is indicated for adults with metastatic colorectal cancer who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, where appropriate, anti-EGFR therapy.
Although Fruquintinib has been approved in several international markets, it may not always be commercially available in India. For patients whose oncologists recommend this therapy, the Named Patient Program (NPP), also known as the Named Patient Import (NPI) pathway, provides a legal and regulated mechanism to import the medicine for personal use when it is unavailable in the Indian market.

If you or a loved one are navigating this process, understanding what happens after the request is submitted can help you prepare for each stage of the journey.

Understanding the Named Patient Import (NPI) Process

The Named Patient Import (NPI) pathway allows patients in India to legally import small quantities of life-saving medicines for personal use under Rule 36 of the Drugs and Cosmetics Rules. This provision is specifically intended for medicines that are medically necessary but are not marketed or readily available in the country. The process is closely regulated to ensure that patients receive genuine medicines while complying with all applicable regulatory requirements.

Step 1: Submission to CDSCO

Once your oncologist provides a valid prescription along with a medical justification explaining why Fruquintinib is required, an application is prepared and submitted using Form 12A to the appropriate port office of the Central Drugs Standard Control Organization (CDSCO). This application serves as the formal request seeking permission from the Indian regulatory authority to import the medicine for an individual patient.

Step 2: The Review and Approval Phase

After the application is submitted, the CDSCO reviews all supporting documents to verify the authenticity of the request. This includes confirming the treating doctor's registration details, evaluating the medical necessity of the medicine, and ensuring that the submitted documentation is complete. Once the application satisfies all regulatory requirements, the CDSCO issues Form 12B, which serves as the official authorization permitting the import of Fruquintinib. In most cases, this review and approval process is completed within one to two working days, provided there are no discrepancies in the documentation.

Step 3: Sourcing and Customs Clearance

Following the issuance of Form 12B, the medicine is sourced from countries where Fruquintinib is commercially available, such as the United States, Europe, or Australia. Facilitators like 24/7QualityMeds coordinate with authorized suppliers to procure genuine medicine from approved sources. Once shipped to India, the consignment undergoes customs clearance, where Form 12B is presented as proof of regulatory approval. Since the import is intended strictly for personal use, the quantity permitted is generally limited to approximately 100 average doses.

Step 4: Final Delivery and Dispensing

After clearing customs, the medicine undergoes a final quality and documentation check by registered pharmacists before being dispatched. Depending on the patient's treatment plan, Fruquintinib is delivered either directly to the patient's residence or to the treating hospital, allowing therapy to begin without unnecessary delays.

Basic Information Required for Patients in India

To ensure that the NPP application is processed smoothly, patients should keep all required documentation ready before initiating the request. This includes a valid prescription from a doctor, who is registered with the medical council of India, specifying the medicine name, dosage, quantity, and duration of treatment, along with a medical justification confirming that Fruquintinib is clinically necessary and unavailable in the Indian market. Patients will also need government-issued identity proof, such as an Aadhaar card, PAN card details, and recent diagnostic reports supporting the diagnosis. During the final stages of procurement, additional documents such as an Authority Letter, Doctor Consent Letter, and Drug Utilization Letter may also need to be completed.

The Role of Facilitators

Importing a medicine through the Named Patient Program involves regulatory documentation, international sourcing, shipping logistics, and customs compliance. For this reason, many patients choose to work with experienced facilitators who manage the process on their behalf. These organizations provide transparency regarding the availability and pricing of Fruquintinib, ensure compliance with all CDSCO requirements, source medicines only from genuine manufacturers or authorized distributors, and maintain appropriate storage conditions throughout transportation. Fruquintinib should be stored at a controlled room temperature of 20°C to 25°C to preserve its quality and efficacy.

Accessing Fruquintinib through the Named Patient Program is a structured and legally regulated process designed to help patients obtain essential medicines that are not readily available in India. While the procedure involves multiple regulatory steps, it is designed to be efficient and patient-focused. By working closely with their oncologist and a reliable import facilitator, patients can navigate the CDSCO approval process with confidence and gain timely access to this important targeted therapy.